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Daniel J. Bertges, MD, RVT,a for the Vascular Study Group of New England, Burlington, Vt; Biddeford, Me;
and Lebanon, NH
Objective: The goal of this study was to evaluate whether protamine usage after carotid endarterectomy (CEA) increased
within the Vascular Study Group of New England (VSGNE) in response to studies indicating that protamine reduces
bleeding complications associated with CEA without increasing the risk of stroke.
Methods:We reviewed 10,059 CEAs, excluding concomitant coronary bypass, performed within the VSGNE from January
2003 to July 2012. Protamine use and reoperation for bleeding were evaluated monthly using statistical process control.
Twelve centers and 77 surgeons entering the VSGNE between 2003 and 2008 were classiﬁed as original participants, and
14 centers and 60 surgeons joining after May 2009 were considered new. Protamine use for surgeons was categorized as
rare (<10%), selective (10%-80%), or routine (>80%). Outcome measures were in-hospital reoperation for bleeding,
postoperative myocardial infarction (POMI), and stroke or death.
Results: Two signiﬁcant increases occurred in protamine use for all VSGNE centers over time. From 2003 to 2007, the
protamine rate remained stable at 43%. In 2008, protamine usage increased to 52% (P < .01), coincident with new centers
joining the VSGNE. Protamine usage then increased to 62% in 2010 (P < .01), shortly after the presentations of the data
showing a beneﬁt of protamine. This effect was due to 10 surgeons in the original VSGNE centers who increased their usage
of protamine: six surgeons from rare use to selective use and four surgeons to routine use. Reoperation for bleeding was
reduced by 0.84% (relative risk reduction, 57.2%) in patients who received protamine (0.6% vs 1.44%; P < .001). There were
no differences in POMI (1.1% vs 1.09%) or stroke or death (1.1% vs 1.03%) between protamine treated and untreated
patients, respectively. Reoperation for bleeding was decreased for surgeons who used protamine routinely (0.5%; P < .001)
compared with selective (1.4%) and rare users (1.5%) of protamine. There were no differences in POMI (0.9%, 1.2%, 1.1%;
P[ .720) and stroke or death rates (1.0%, 1.2%, 1.0%; P[ .656) for rare, selective, and routine users of protamine.
Conclusions: Protamine use increased over time by VSGNE surgeons, most signiﬁcantly after the presentations of
VSGNE-derived data showing the beneﬁt of protamine, and was associated with a decrease in reoperation for bleeding.
Improvements in processes of care and outcomes can be achieved in regional quality groups by sharing safety and efﬁcacy
data. (J Vasc Surg 2013;58:1518-24.)The Vascular Study Group of New England (VSGNE)
was designed as a regional collaborative to improve vascular
health care by collecting and analyzing data for key vascular
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8improvement initiatives have successfully improved the
perioperative medical management of vascular patients
with increased use of aspirin, b-blockers, and statins.1,2
The collaborative has monitored and improved the re-
gional rate of patching during conventional carotid endar-
terectomy (CEA), which reduced the restenosis rate at the
1-year follow-up.3
VSGNE data have also provided a basis for substantial
clinical research with a quality improvement focus, such as
developing a cardiac risk prediction model to improve
patient selection.4 Other research studies have used the
power of this large database to answer clinical questions
such as whether protamine should be administered during
CEA.5 This study showed a threefold reduction in reoper-
ation for bleeding, with no increase in potential thrombotic
complications, a ﬁnding that required a data set of >4000
patients to prove signiﬁcance.
An unanswered question is whether and how rapidly
such a ﬁnding might change clinical practice. Results con-
cerning protamine use during CEA were presented by
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2009, at the Society for Vascular Surgery (SVS) plenary
session in June 2009, and were published in the Journal
of Vascular Surgery in March 2010. The purpose of our
current study was to determine whether this information
would increase protamine usage during CEA in a region
where the practice pattern was evenly split before these
presentations. Secondarily, we sought to conﬁrm the bene-
ﬁcial effects of protamine during CEA in a patient cohort
more than twice as large as the original study.
METHODS
Patients and database. We reviewed 10,059 CEAs
performed in 9260 patients in the VSGNE from January
2003 to July 13, 2012. During the study period, 787
patients had two CEAs and six patients had three
CEAs. Among the study patients, carotid disease was
asymptomatic in 6034 (60%) and symptomatic in 4025
(40%). The analysis did not include 235 patients who
had a concomitant coronary artery bypass procedure.
From 2003 to 2012, there were 26 centers and 137
surgeons in the VSGNE. Of these, 12 centers and 77
surgeons were categorized as “original” because they
joined the VSGNE before 2008, and 14 centers and 60
surgeons were categorized as “new” because they joined
the VSGNE after 2008.
Study end points. Protamine administration intrao-
peratively or after CEA was recorded in the registry. Four
patients were excluded from analysis due to lack of prot-
amine data. Surgeons were categorized into three groups
according to their practice pattern of protamine use: (1)
“rare” if protamine was used in <10% of CEAs; (2) “selec-
tive” if protamine was used in 10% to 80% of CEAs; or (3)
“routine” if protamine was used in >80% of the patients.
Surgeons who performed <10 CEAs were excluded from
analysis of protamine use practice pattern. The registry
captures the use of heparin and protamine but does not
record dosages. Heparin activity, as measured by partial
thromboplastin time or activated clotted time, is not
recorded in the registry.
The primary end point was the rate of protamine use
during CEA. Secondary end points included reoperation
for bleeding after CEA, postoperative myocardial infarction
(POMI), and the combined outcome of any stroke or
death during the same hospitalization. POMI was deﬁned
as a troponin elevation according to individual center
criteria, electrocardiogram with new Q waves, new ST or
T-wave changes, or documentation by clinical criteria or
echocardiogram or other imaging modality. Stroke severity
was deﬁned as major if it resulted in blindness or disability
or caused nonindependent living and as minor if symptoms
were nondisabling. Bleeding after CEA was captured as
reoperation for bleeding. The registry does not record
re-exploration for bleeding after skin closure but before
leaving the operating room or more minor neck hema-
tomas that did not require reoperation. The VSGNE also
records reoperation for a neurologic event, which was
not examined in this study. Use of drains was not includedin the analysis because these data were only recorded in the
VSGNE after 2010.
Intervention. The beneﬁts of protamine were previ-
ously presented at the VSGNE semiannual meeting in April
2009 and the Vascular Annual Meeting in June 2009 and
later reported by Stone et al in the Journal of Vascular
Surgery publication in March 2010.5 However, no formal
VSGNE quality improvement interventions were under-
taken to increase the use of protamine, such as team
meetings or plan, do, study, act cycles. Further, feedback
on protamine use was not provided to individual surgeons
or centers during the time period included in this study.
Statistical analysis: statistical process control. The
protamine usage rate was evaluated monthly in a statistical
process control (SPC) chart. A P chart was used because
the total number of procedures per month varied from
46 to 167 over time, as more centers joined the VSGNE.
SPC charts distinguish special cause variation from random
variation.6
If a process is “stable,” then the protamine usage rate
will vary between the upper and lower control limits, which
are set at 3 sigma (w3 standard deviations from the mean).
Any increase or decrease in the rate of protamine usage
within this range is considered random variation. If a signif-
icant change occurs in the system, then the SPC chart indi-
cates special cause variation. Although there are various
deﬁnitions for determining a special cause variation, we
used the commonly accepted criterion of 8 or more consec-
utive points above the central line. A shift in the data to this
degree has a probability of less than 0.01. The central line
was established and ﬁxed using the ﬁrst 2 years of data
collection (number of procedures using protamine divided
by total number of procedures). SPC charts were used to
evaluate protamine usage rate for the all centers combined
and the original centers alone. Separate SPC charts were
constructed for surgeons with rare and selective protamine
use. Reoperation for bleeding was also measured with a P
chart.
For each of the surgeons’ protamine usage categories,
the c2 test was used to determine whether there was
a difference in protamine usage between original and new
centers for procedures done in 2010 or later. The c2 test
was also used to determine whether the three outcome
variables (reoperation for bleeding, POMI, and stroke or
death) were different if protamine was used. A P value
of # .05 was considered statistically signiﬁcant. Statistical
analysis was performed using STATA 12.0 software (Stata-
Corp LP, College Station, Tex).
RESULTS
Protamine use. Over the entire study from 2003 to
2012, protamine was used during 53% of CEAs. As shown
in Fig 1, protamine use remained stable from 2003
through 2007 at 43%. Beginning in January 2008, there
was a signiﬁcant increase in protamine use to 52%
(P < .01). This was due to new centers and surgeons
joining the VSGNE with a higher than average protamine
usage rate. By November 2009, w6 months after two
Fig 2. Reoperation for bleeding among the 10 improvers
compared to surgeons with rare and routine protamine use.
Fig 1. Statistical process control (SPC) chart shows protamine use during carotid endarterectomy (CEA) for all
surgeons participating in the Vascular Study Group of New England (VSGNE) from January 2003 to July 2012.
LCL, Lower control limit; SVS, Society for Vascular Surgeons; UCL, upper control limit.
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reduce reoperation for bleeding, the rate of protamine use
showed a special cause increase to 62% (P < .01) and
remained elevated through the end of the study. To account
for the possible confounding effects of new centers entering
the VSGNE, we performed a separate P chart analysis of
only the original centers and surgeons. The results were
similar, with protamine use increasing to 50% in early 2008
and to 63% starting after April 2010 following the presen-
tations and journal article (Supplementary Fig, online only).
We compared cohorts from 2003 to 2008 and from 2008 to
2012 and found similar patient and operative characteristics,
except for a higher rate of patients aged >80 years, lower
rate of symptomatic carotid disease, and fewer eversion
CEAs in the latter group (Supplementary Table, online
only). The rate of patch angioplasty, which has been asso-
ciated with a decrease in reoperation for bleeding, and use of
perioperative antiplatelet agents was similar.
Rare, selective, and routine protamine use by
surgeons at the original VSGNE centers. During the
entire study duration, 77 surgeons from the 12 original
VSGNE centers performed 8372 CEAs (83%); of these,
14 performed <10 procedures and were not categorized
into protamine usage groups. Twenty-ﬁve surgeons were
“routine” protamine users and performed 44% of the
procedures. Their protamine usage rate was $94%
throughout the study. Nineteen surgeons were “selective”
protamine users and performed 25% of the procedures.
Their protamine usage rate was 15% until 2009, when it
increased to >50% through 2012. Nineteen surgeons were
“rare” protamine users and performed 31% of the proce-
dures. Their protamine usage rate was stable at 4% from
until 2009, but it increased signiﬁcantly to 10% by August
2010, after VSGNE presentations and publication by Stone
et al.5 By analysis of individual surgeon practice, 10 of theoriginal 77 surgeons in the VSGNE signiﬁcantly increased
their use of protamine. Of these, six surgeons went from rare
to selective use and four went from rare or selective use to
routine use.
For the 10 surgeons (improvers), protamine usage
increased from 7% to 49% and their rate of reoperation
for bleeding was reduced from 1.8% to 1% (Fig 2). This
difference was not statistically signiﬁcant, likely due to
a small sample size with a power of .31 at a ¼ .05. From
2003 to 2008, the improvers’ reoperative rate was not
signiﬁcantly different from the surgeons (n ¼ 10) who
rarely used protamine (1.8% vs 1.6%; Fisher exact test
P ¼ .115). This is an expected ﬁnding because both groups
rarely used protamine during this time frame.
From 2003 to 2008, the improvers’ rate of reoperation
for bleeding was signiﬁcantly higher than the 17 surgeons
who used protamine routinely (1.8% vs 0.7%; P ¼ .012).
Table. Postoperative complications stratiﬁed by surgeon protamine use
Protamine use categories
Reoperation for bleeding (P < .001a) POMI (P ¼ .720) Stroke or death (P ¼ .656)
No Yes No Yes No Yes
No. (%) No. (%) [95% CI] No. (%) No. (%) [95% CI] No. (%) No. (%) [95% CI]
Rare (<10%) 2706 (98.5) 40 (1.5) [29-54] 2718 (99.1) 26 (0.9) [17-38] 2719 (99) 27 (1.0) [18-39]
Selective (10% to 80%) 2554 (98.6) 35 (1.4) [24-49] 2559 (98.8) 30 (1.2) [20-43] 2558 (98.8) 31 (1.2) [21-44]
Routine (>80%) 4545 (99.5) 24 (0.5) [15-36] 4517 (98.9) 51 (1.1) [38-67] 4524 (99) 45 (1.0) [32-60]
CI, Conﬁdence interval; POMI, postoperative myocardial infarction.
ac2.
Fig 3. Statistical process control (SPC) chart shows reoperation for bleeding after carotid endarterectomy (CEA) for
all surgeons participating in the Vascular Study Group of New England (VSGNE) from January 2003 to July 2012.
SVS, Society for Vascular Surgeons; UCL, upper control limit.
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reduced to 1%, which was not statistically signiﬁcantly
different (P ¼ .08). Notably, these surgeons’ protamine
usage (49%) did not reach the level of surgeons who
routinely used protamine (96%).
Secondary outcome measures. Of patients who did
not receive protamine during CEA, 1.4% required reoper-
ation for bleeding compared with only 0.6% of patients
who received protamine (P < .001). In contrast, protamine
use had no effect on the rate of POMI (1.1% with, 1.1%
without protamine; P > .99) or stroke or death (1.1%
with, 1.0% without protamine; P ¼ .740). There were no
differences in stroke or death rates in patients with symp-
tomatic carotid disease based on protamine use (1.3%
rare, selective 1.4%, routine 1.5%; P ¼ .412).
Surgeons using protamine routinely had the lowest rate
of reoperation for bleeding, at 0.5% (Table). There was no
difference in the rate of POMI or stroke or death between
rare, selective, and routine users of protamine. Using SPC,
we identiﬁed a decrease in the rate of reoperation forbleeding after CEA from 1.2% to 0.7% beginning in the
fourth quarter of 2009 (Fig 3), after the presentation by
Stone et al at VSGNE and SVS Vascular Annual Meeting.5
DISCUSSION
This study reports an increase in the use of protamine
during CEA coinciding with presentations and a publica-
tion of VSGNE-derived data documenting the safety and
beneﬁts of heparin reversal. Stone et al5 reviewed 4587
CEAs within the VSGNE and found no differences in
stroke rates (0.78% vs 1.15%; P ¼ .2), myocardial infarction
(1.1% vs 0.91%; P ¼ .51), or death (0.23% vs 0.32%; P ¼
.57), with a decrease in reoperation for bleeding (0.64%
vs 1.66%; P ¼ .001) in treated and untreated patients,
respectively.5 This study extends those ﬁndings, showing
an absolute risk reduction of 0.84% and relative risk reduc-
tion of 57.2% in reoperation for bleeding in a large cohort
more than double the original population.
On the basis of the prior study, we examined surgeon
practice patterns and outcomes. We used an SPC chart to
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tion of the increase in protamine use with the Stone
et al5 data strongly suggests a direct link between the
reporting of shared data and changes in individual surgeon
practice patterns. To further validate this conclusion, we
were able to contact nine of 10 surgeons who increased
their protamine usage to ask them what inﬂuenced their
change in protamine usage. Attempts at a more formal
survey of all surgeons were invalid due to a low response
rate. All nine surgeons responded that this was due to
the presentations or the journal article, or both. One
quotation from this electronic survey was, “The change
was related to the paper out of the VSGNE that showed
beneﬁt in decreased bleeding, return to OR, LOS, etc,
without any signiﬁcant increased risk associated with use.”
Unlike our prior quality improvement projects to
increase perioperative medication usage, we did not iden-
tify bleeding after CEA as a speciﬁc quality improvement
project and did not recommend a threshold for protamine
use. A formal quality improvement team was not formed,
and tests of change were not conducted. Instead, the
simple reporting of the beneﬁt and safety of protamine
appears responsible for a measurable practice change.
This rapidity of this change was remarkable.
Research has shown that rapid translation of clinical
research ﬁndings into current practice is difﬁcult.7-9 The
method by which clinicians translate research into practice
has been described as a process of awareness to acceptance
to adoption.9 Traditionally, scientiﬁc meetings and journals
have focused on continuing medical education to promote
awareness and acceptance, with little attention to adoption.
Numerous strategies have been espoused to improve the
adoption of clinical research. These include the dissemina-
tion of practice guidelines by opinion leaders or profes-
sional societies, “coproduction” of knowledge, auditing
with performance feedback, computerized decision
support, and academic detailing.7,8,10,11 Coproduction of
research has been described as a partnership between
academic and clinical staff to design research studies imme-
diately relevant to practice.10 Academic detailing refers to
personalized education often occurring directly in the prac-
tice setting. Because change in practice is complex, the
most successful initiatives combine multiple types of inter-
ventions to affect change.
The coproduction of knowledge strategy is inherent
within the VSGNE. Our working theory is that surgeons
who contribute to the VSGNE feel “ownership” of the
data and are thus more likely to respond to the data with
practice change. The VSGNE also uses academic detailing
through direct contact among surgeons in the region. Our
hypothesis is supported by the collaborative work of the
Northern New England Cardiovascular Disease Study
Group, which reduced mortality after coronary artery
bypass grafting by providing feedback from outcomes
data, training in continuous quality improvement tech-
niques, and site visits. Postoperative mortality decreased
by 24%, demonstrating that such efforts may have a direct
effect on practice patterns and can improve patientoutcomes.12 Our ﬁndings should encourage regional
quality groups to use SPC methodology in real time and
share these results with their members.
From a scientiﬁc standpoint, our current study rein-
forces the initial VSGNE conclusions by Stone et al5 in
a study population of now >10,000 CEAs. This conclusive
demonstration of a beneﬁt of protamine without throm-
botic complication is important, because several early retro-
spective studies and small, randomized trials reported an
association between protamine use and an increase in post-
operative stroke.13-15 Other literature, including a report
from the General Anaesthetic vs Local Anaesthetic for
Carotid Surgery (GALA) Trial, has shown conﬂicting
evidence, with reduction in hematoma when using prot-
amine but no differences in reoperation rates.16,17
The rate for returning to the operating room for
bleeding in our study was 1.4% for those who did not
receive protamine. For patients who received protamine,
the reoperation for bleeding was signiﬁcantly reduced to
0.6%, with the lowest bleeding rates (0.4%) attributed to
surgeons who routinely used protamine. The need for
reoperation in even a small percentage of our patients is
not without consequences. Stone et al5 found that these
patients have a higher incidence of clinically signiﬁcant
POMI, stroke, and in-hospital mortality. We estimate
that the number needed to treat is 111 patients to prevent
one reoperation for bleeding.
The National Hospital Discharge Survey documented
140,000 CEAs were performed in 2009.18 National data
on protamine use during CEA are not available. Survey
data from the SVS have estimated protamine use at
between 48% and 54%.19,20 Extrapolating from these
data, w64,400 to 72,800 patients did not receive prot-
amine during CEA. Administration of protamine to the
remaining patients could potentially prevent 540 to 610
reoperations for bleeding each year and the adverse
outcomes associated with reoperation. Data on protamine
use from the Vascular Quality Initiative will help clarify
these hypothetical calculations. Although we did not
consider cost, at an expense of $0.56-$0.71/mg, prot-
amine is likely very cost effective.
Few nationally endorsed quality indicators exist for
vascular surgery. Metrics from the Surgical Care Improve-
ment Project focus mainly on prophylactic antibiotic
use.21 Because infection is a rare complication of CEA, other
metrics are required to better assess the quality of care.
Mortality and volume are under consideration as quality
measures by the Agency for Healthcare Research and
Quality.22 Although use of patch angioplasty was recom-
mended based on grade 1/level A evidence in the SVS prac-
tice guidelines for the management of extracranial carotid
disease, patching is not a quality measure for conventional
CEA.23 Protamine use was not addressed in this SVS docu-
ment nor by the European Society for Vascular Surgery
guidelines.24 We believe that protamine reversal of heparin
during CEA is also a useful quality measure.
This study has some limitations. Although the VSGNE
captures an extensive number of data points, other
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affected the rate of reoperation for bleeding. We recognize
that other factors could contribute to the increase in use of
protamine in the VSGNE, such as discussions within a prac-
tice group that reveal variation in practice. However, our
query of the surgeons who increased protamine usage
conﬁrmed that the Stone el al presentations or the journal
article, or both, prompted their change, despite previous
controversy in the literature about this subject.
Fewer symptomatic patients underwent CEA in the
2008 to 2012 cohort, but it is unlikely this masked any
deleterious effect of protamine, given the nearly identical
rates of stroke and death between protamine treatment
groups. We analyzed the effect of protamine on signiﬁcant
postoperative hemorrhage, POMI, and stroke or death,
but did not have data on other adverse reactions such as
anaphylaxis, pulmonary hypertension, and systemic hypo-
tension. However, we know that such complications were
not severe enough to inﬂuence mortality. We also could
not account for the dosing of heparin or protamine used
by surgeons. However, such dosing likely varies widely,
which provides even more support for the beneﬁcial effect
of protamine.
CONCLUSIONS
Protamine use increased over time by VSGNE
surgeons due to the presentations of VSGNE-derived
data showing the beneﬁt of protamine. The increase in
protamine use was associated with a decrease in reoperation
for bleeding after CEA, without an increase in the inci-
dence of stroke or POMI. This demonstrates that improve-
ments in a process of care leading to improved outcomes
can be achieved in regional quality groups by sharing safety
and efﬁcacy data.
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Supplementary Fig (online only). Statistical process control (SPC) chart shows protamine use during carotid
endarterectomy (CEA) by surgeons from original participating centers from January 2003 to July 2012. LCL, Lower
control limit; SVS, Society for Vascular Surgeons; UCL, upper control limit; VSGNE, Vascular Study Group of New
England.
Supplementary Table (online only). Patient and
operative characteristics over time
Variables
2003-2007 2008-2012
Pa
(n ¼ 4087),
%
(n ¼ 5972),
%
Preoperative characteristics
Age, years
60-69 31.3 32.6 .18
70-79 38.3 36.7 .1
80 13.7 17.1 <.001
Male 59.7 60.0 .37
Prior contralateral CEA 13.7 14.5 .85
Symptomatic carotid disease
Any symptoms 58.7 53.2 <.001
Ocular
Ipsilateral 14.6 12.7 .003
Contralateral 1.9 1.7 .25
Cortical, ipsilateral
Transient ischemic attack 17.6 11.3 <.001
Stroke 8.9 9.6 <.001
Cortical, contralateral
Transient ischemic attack 1.9 4.2 <.001
Stroke 1.9 3.8 <.001
Vertebrobasilar 2.5 2.6 .67
Preoperative medications
Aspirin 84.9 89.3 >.99
Clopidogrel 16.8 18.3 .97
Aspirin and clopidogrel 87.6 92.4 1
Operative characteristics
Redo CEA 2.1 2.4 .82
Patch angioplasty 80.6 92.6 >.99
Eversion CEA 13.0 7.1 <.001
Dextran 5.5 9.4 >.99
CEA, Carotid endarterectomy.
ac2.
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